MDXH

MDxHealth SA
CAPPED RATING

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

MDxHealth SA (MDXH) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (A-); its weakest is Revisions (F). The rating has held at C- for 3 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.0 / 5.0
C-
Value
B-
Factor Score 3.0 / 5.0
Growth
C
Factor Score 2.2 / 5.0
Profitability
A-
Factor Score 4.0 / 5.0
Momentum
D-
Factor Score 0.7 / 5.0
Revisions
F
Factor Score 0.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.4
EV / EBITDA -6.3
Rev Growth YoY 2.3%
Gross Margin 62.9%
Price Return 3M -82.7%
Price Return 12M -96.8%
Catalyst Signal 0.00
Market Cap $13.4M
TTM Revenue $114.0M
Price / Sales 0.1
ROE N/A

Historical Factor Score Progression

Held C- for 3 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 B- (3.0) C (2.2) A- (4.0) D- (0.7) F (0.0) C- (2.0)
2026-11-06 B- (3.0) C (2.2) A- (4.0) F (0.6) F (0.0) C- (2.0)
2026-10-30 B- (3.0) C (2.2) A- (4.0) F (0.7) F (0.0) C- (2.0)
2026-10-23 B- (3.0) C (2.2) A- (4.0) F (0.7) F (0.0) C- (2.0)
2026-10-16 B- (3.0) C (2.2) A- (4.0) C- (2.0) C+ (2.6) C+ (2.8)
Page 1 of 3